{
  "trial_id": "NCT00330993",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "collected during the screening process will be destroyed",
      "label": "met"
    },
    {
      "criterion": "Potential subjects interested in participation will be scheduled for a screening visit.",
      "label": "met"
    },
    {
      "criterion": "Each subject will undergo a minimum of 3 visits all of which will be performed in the Family Planning Research Office at Magee-Womens Hospital.",
      "label": "met"
    },
    {
      "criterion": "She will also receive a minimum of 3 follow-up telephone calls.",
      "label": "met"
    },
    {
      "criterion": "SCREENING AND ENROLLMENT: Visit length 1 \u00bd hours.",
      "label": "unknown"
    },
    {
      "criterion": "After obtaining consent for a screening ultrasound evaluation, a transvaginal and a transabdominal ultrasound examination will be performed to ascertain gestational age.",
      "label": "met"
    },
    {
      "criterion": "Written informed consent will be obtained at the screening visit prior to any research activities.",
      "label": "met"
    },
    {
      "criterion": "A HIPAA compliant 'Release of Medical Records' form will be signed to allow future access to medical records related to any care provided during the study by another health care provider.",
      "label": "unknown"
    },
    {
      "criterion": "VISIT 1: The subject will return prior to reaching 64 days gestation. This day will be considered Study Day 1. Visit length 30 minutes.",
      "label": "met"
    },
    {
      "criterion": "The research staff will administer a pre-study questionnaire. The subject will complete a Visual Analogue Scale (VAS) assessment.",
      "label": "unknown"
    },
    {
      "criterion": "Eligibility criteria will be reviewed and, if indicated by a history of bleeding since screening, a vaginal ultrasound will be performed.",
      "label": "met"
    },
    {
      "criterion": "A licensed clinician will distribute the medications after completion of the questionnaire. The medications will be kept in a locked file in the research office and a log will be generated to track medication usage, lot numbers, and expiration dates.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "treatment of an early pregnancy failure",
      "label": "not_met"
    },
    {
      "criterion": "contraindication to mifepristone (known allergy to mifepristone, chronic corticosteroid administration, adrenal disease)",
      "label": "unknown"
    },
    {
      "criterion": "contraindication to misoprostol (glaucoma, mitral stenosis, sickle cell anemia, poorly controlled seizure disorder, or known allergy to prostaglandin)",
      "label": "not_met"
    },
    {
      "criterion": "known or suspected extrauterine pregnancy",
      "label": "unknown"
    },
    {
      "criterion": "known or suspected pelvic infection",
      "label": "unknown"
    },
    {
      "criterion": "hemoglobin <10 mg/dL",
      "label": "not_met"
    },
    {
      "criterion": "known clotting defect or receiving anticoagulants",
      "label": "unknown"
    },
    {
      "criterion": "cardiovascular disease (angina, valvular disease, arrhythmia, or cardiac failure)",
      "label": "not_met"
    },
    {
      "criterion": "current breastfeeding",
      "label": "not_met"
    }
  ],
  "notes": "The patient is a healthy woman with no underlying diseases. She has been taking daily multivitamins and anti-hypertensive drugs, but there is no indication of any contraindications to the study.",
  "_meta": {
    "topic_id": "69",
    "trial_id": "NCT00330993",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}